Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009
Mon, April 13, 2009
Fri, April 10, 2009
Thu, April 9, 2009
Wed, April 8, 2009
Tue, April 7, 2009
Mon, April 6, 2009
Fri, April 3, 2009
Thu, April 2, 2009
Wed, April 1, 2009
Tue, March 31, 2009
Mon, March 30, 2009
Fri, March 27, 2009
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009

DUSA Pharmaceuticals, Inc.: DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2008 Financial Results and Corpo


//health-fitness.news-articles.net/content/2009/ .. -full-year-2008-financial-results-and-corpo.html
Published in Health and Fitness on Friday, March 6th 2009 at 5:37 GMT, Last Modified on 2009-03-06 05:38:26 by Market Wire   Print publication without navigation


WILMINGTON, MA--(Marketwire - March 6, 2009) - DUSA Pharmaceuticals, Inc. (NASDAQ: [ DUSA ]) announces that its corporate highlights and year end financial results press release will be issued on Wednesday, March 11th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

 Wednesday, March 11 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314 Password - DUSA For International callers use 502-498-8422 A recorded replay of the call will be available approximately 15 minutes following the call North American callers 877.863.0350 International callers 858.244.1268 

The call will be accessible on our web site approximately four hours following the call at [ www.dusapharma.com ].

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp. DUSA is also researching additional indications for Levulan PDT, including oral leukoplakia in collaboration with the National Institutes of Health (NIH) and the prevention of AKs and SCCs in immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Massachusetts. Please visit the company's Web site at [ www.dusapharma.com ] for more information.


Publication Contributing Sources

Similar Health and Fitness Publications